

Title (en)

NOVEL TUMOR MARKERS SELECTED FROM A GROUP OF cAMP-REGULATORY PATHWAY MEMBERS

Title (de)

AUS EINER GRUPPE AUS CAMP-REGULATORISCHEN SIGNALWEGEELEMENTEN AUSGEWÄHLTE NEUE TUMORMARKER

Title (fr)

NOUVEAUX MARQUEURS TUMORAUX SÉLECTIONNÉS PARMI UN GROUPE D'ÉLÉMENTS DE LA VOIE DE RÉGULATION DES AMPC

Publication

**EP 2473853 A1 20120711 (EN)**

Application

**EP 10760034 A 20100902**

Priority

- EP 09169428 A 20090903
- EP 09169423 A 20090903
- IB 2010053944 W 20100902
- EP 10760034 A 20100902

Abstract (en)

[origin: WO2011027312A1] The present invention relates to a tumor marker or group of tumor markers associated with the progression of a neoplastic disease from a less progressed stage to a more progressed stage, wherein the expression of the tumor marker or group of tumor markers is modified when comparing the expression of the tumor marker or group of tumor markers in the less progressed stage to the expression in the more progressed stage, wherein said tumor marker or group of tumor markers comprises a tumor marker selected from a group of cAMP -regulatory pathway members comprising A-kinase anchor protein 6 (AKAP6), cyclic nucleotide-gated cation channel beta-3 (CNBG3), cGMP-dependent protein kinase 2 (KGP2), A-kinase anchor protein 1 (AKAP1), A-kinase anchor protein 9 (AKAP9), A-kinase anchor protein 13 (AKAP13), High affinity cGMP-specific 35-cyclic phosphodiesterase 9A (PDE9A), cAMP-dependent protein kinase type I-beta regulatory subunit (PRKAR1B), and cAMP-specific 35-cyclic phosphodiesterase 4C (PDE4C). The present invention further relates to a composition for diagnosing, detecting, graduating, monitoring or prognosticating a neoplastic disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage comprising affinity ligands for the expression products of the tumor markers, to corresponding methods, and to the use of said tumor markers for detecting, diagnosing, graduating, monitoring or prognosticating a neoplastic disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage. The present invention further relates to a corresponding immunoassay, to a method of identifying an individual for eligibility for a neoplastic disease therapy, as well as to a pharmaceutical composition based on the inhibition and/or activation of the expression of said tumor markers.

IPC 8 full level

**G01N 33/574** (2006.01)

CPC (source: EP)

**G01N 33/57484** (2013.01); **G01N 2800/56** (2013.01)

Citation (search report)

See references of WO 2011027312A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)

**WO 2011027312 A1 20110310**; EP 2473853 A1 20120711

DOCDB simple family (application)

**IB 2010053944 W 20100902**; EP 10760034 A 20100902